Administration of probiotic mixture DM#1 ameliorated 5-fluorouracil–induced intestinal mucositis and dysbiosis in rats

Nutrition

Volumn 33, Issue , 2017, Pages 96-104

  Tang, Yan ^a   Wu, Yingtao ^a   Huang, Ziyi ^a   Dong, Weiwei ^a   Deng, Ying ^a   Wang, Fengjiao ^a   Li, Ming ^a   Yuan, Jieli ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

5 fluorouracil; Intestinal dysbiosis; Intestinal mucositis; Probiotics; Toll like receptors

Indexed keywords

FLUOROURACIL; INTERLEUKIN 4; INTERLEUKIN 6; MYELOPEROXIDASE; PROBIOTIC AGENT; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR; CYTOKINE; MESSENGER RNA; TOLL LIKE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; BIFIDOBACTERIUM BREVE; BODY WEIGHT; CONTROLLED STUDY; DENATURING GRADIENT GEL ELECTROPHORESIS; DRUG DOSE COMPARISON; DYSBIOSIS; ENZYME ACTIVITY; GENE EXPRESSION; HISTOPATHOLOGY; HOMEOSTASIS; INTESTINAL BARRIER FUNCTION; INTESTINAL MUCOSITIS; INTESTINE FLORA; INTESTINE FUNCTION; INTESTINE INFARCTION; INTESTINE INFECTION; INTESTINE MUCOSA PERMEABILITY; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; MALE; MORTALITY; MUCOSA INFLAMMATION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; STREPTOCOCCUS THERMOPHILUS; TLR2 GENE; TLR4 GENE; TLR9 GENE; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; GENETICS; ILEUM; INFLAMMATION; INTESTINE MUCOSA; METABOLISM; MUCOSITIS; PATHOLOGY; PERMEABILITY; RANDOMIZATION;

ANIMALS; CYTOKINES; DYSBIOSIS; FLUOROURACIL; GASTROINTESTINAL MICROBIOME; ILEUM; INFLAMMATION; INTERLEUKIN-4; INTERLEUKIN-6; INTESTINAL MUCOSA; MALE; MUCOSITIS; NEUTROPHIL INFILTRATION; PERMEABILITY; PROBIOTICS; RANDOM ALLOCATION; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84978906769     PISSN: 08999007     EISSN: 18731244     Source Type: Journal    
DOI: 10.1016/j.nut.2016.05.003     Document Type: Article

References (45)

1. [1] Decker-Baumann, C., Buhl, K., Frohmuller, S., von Herbay, A., Dueck, M., Schlag, P.M., Reduction of chemotherapy-induced side-effects by parenteral glutamine supplementation in patients with metastatic colorectal cancer. Eur J Cancer 35 (1999), 202–207.
2. [2] Soares, P.M., Mota, J.M., Gomes, A.S., Oliveira, R.B., Assreuy, A.M., Brito, G.A., et al. Gastrointestinal dysmotility in 5-fluorouracil-induced intestinal mucositis outlasts inflammatory process resolution. Cancer Chemother Pharmacol 63 (2008), 91–98.
3. [3] Daniele, B., Secondulfo, M., De Vivo, R., Pignata, S., De Magistris, L., Delrio, P., et al. Effect of chemotherapy with 5-fluorouracil on intestinal permeability and absorption in patients with advanced colorectal cancer. J Clin Gastroenterol 32 (2001), 228–230.
4. [4] Duncan, M., Grant, G., Oral and intestinal mucositis—causes and possible treatments. Aliment Pharmacol Ther 18 (2003), 853–874.
5. [5] Von Bultzingslowen, I., Adlerberth, I., Wold, A.E., Dahlen, G., Jontell, M., Oral and intestinal microflora in 5-fluorouracil treated rats, translocation to cervical and mesenteric lymph nodes and effects of probiotic bacteria. Oral Microbiol Immunol 18 (2003), 278–284.
6. [6] Lin, X.B., Dieleman, L.A., Ketabi, A., Bibova, I., Sawyer, M.B., Xue, H., et al. Irinotecan (CPT-11) chemotherapy alters intestinal microbiota in tumour bearing rats. PLoS One, 7, 2012, e39764.
7. [7] Maynard, C.L., Elson, C.O., Hatton, R.D., Weaver, C.T., Reciprocal interactions of the intestinal microbiota and immune system. Nature 489 (2012), 231–241.
8. [8] van Vliet, M.J., Harmsen, H.J., de Bont, E.S., Tissing, W.J., The role of intestinal microbiota in the development and severity of chemotherapy-induced mucositis. PLoS Pathog, 6, 2010, e1000879.
9. [9] Stringer, A.M., Interaction between host cells and microbes in chemotherapy-induced mucositis. Nutrients 5 (2013), 1488–1499.
10. [10] Whitford, E.J., Cummins, A.G., Butler, R.N., Prisciandaro, L.D., Fauser, J.K., Yazbeck, R., et al. Effects of Streptococcus thermophilus TH-4 on intestinal mucositis induced by the chemotherapeutic agent, 5-Fluorouracil (5-FU). Cancer Biol Ther 8 (2009), 505–511.
11. [11] Prisciandaro, L.D., Geier, M.S., Butler, R.N., Cummins, A.G., Howarth, G.S., Probiotic factors partially improve parameters of 5-fluorouracil-induced intestinal mucositis in rats. Cancer Biol Ther 11 (2011), 671–677.
12. [12] Justino, P.F., Melo, L.F., Nogueira, A.F., Morais, C.M., Mendes, W.O., Franco, A.X., et al. Regulatory role of Lactobacillus acidophilus on inflammation and gastric dysmotility in intestinal mucositis induced by 5-fluorouracil in mice. Cancer Chemother Pharmacol 75 (2015), 559–567.
13. [13] Mauger, C.A., Butler, R.N., Geier, M.S., Tooley, K.L., Howarth, G.S., Probiotic effects on 5-fluorouracil-induced mucositis assessed by the sucrose breath test in rats. Dig Dis Sci 52 (2007), 612–619.
14. [14] Cool, J.C., Dyer, J.L., Xian, C.J., Butler, R.N., Geier, M.S., Howarth, G.S., Pre-treatment with insulin-like growth factor-I partially ameliorates 5-fluorouracil-induced intestinal mucositis in rats. Growth Horm IGF Res 15 (2005), 72–82.
15. [15] Howarth, G.S., Francis, G.L., Cool, J.C., Xu, X., Byard, R.W., Read, L.C., Milk growth factors enriched from cheese whey ameliorate intestinal damage by methotrexate when administered orally to rats. J Nutr 126 (1996), 2519–2530.
16. [16] Wang, Q., Fang, C.H., Hasselgren, P.O., Intestinal permeability is reduced and IL-10 levels are increased in septic IL-6 knockout mice. Am J Physiol Regul Integr Comp Physiol 281 (2001), R1013–R1023.
17. [17] Lee, I.H., Dinudom, A., Sanchez-Perez, A., Kumar, S., Cook, D.I., Akt mediates the effect of insulin on epithelial sodium channels by inhibiting Nedd4-2. J Biol Chem 282 (2007), 29866–29873.
18. [18] Joossens, M., Huys, G., Cnockaert, M., De Preter, V., Verbeke, K., Rutgeerts, P., et al. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. Gut 60 (2011), 631–637.
19. [19] Gafan, G.P., Lucas, V.S., Roberts, G.J., Petrie, A., Wilson, M., Spratt, D.A., Statistical analyses of complex denaturing gradient gel electrophoresis profiles. J Clin Microbiol 43 (2005), 3971–3978.
20. [20] Boon, N., Windt, W., Verstraete, W., Top, E.M., Evaluation of nested PCR-DGGE (denaturing gradient gel electrophoresis) with group-specific 16 S rRNA primers for the analysis of bacterial communities from different wastewater treatment plants. FEMS Microbiol Ecol 39 (2002), 101–112.
21. [21] Clark, R.I., Salazar, A., Yamada, R., Fitz-Gibbon, S., Morselli, M., Alcaraz, J., et al. Distinct shifts in microbiota composition during drosophila aging impair intestinal function and drive mortality. Cell Rep 12 (2015), 1656–1667.
22. [22] Touchefeu, Y., Montassier, E., Nieman, K., Gastinne, T., Potel, G., Bruley des Varannes, S., et al. Systematic review: the role of the gut microbiota in chemotherapy- or radiation-induced gastrointestinal mucositis-current evidence and potential clinical applications. Aliment Pharmacol Ther 40 (2014), 409–421.
23. [23] Honneffer, J.B., Minamoto, Y., Suchodolski, J.S., Microbiota alterations in acute and chronic gastrointestinal inflammation of cats and dogs. World J Gastroenterol 20 (2014), 16489–16497.
24. [24] Talero, E., Bolivar, S., Avila-Roman, J., Alcaide, A., Fiorucci, S., Motilva, V., Inhibition of chronic ulcerative colitis-associated adenocarcinoma development in mice by VSL#3. Inflamm Bowel Dis 21 (2015), 1027–1037.
25. [25] Dai, C., Zheng, C.Q., Meng, F.J., Zhou, Z., Sang, L.X., Jiang, M., VSL#3 probiotics exerts the anti-inflammatory activity via PI3 k/Akt and NF-kappaB pathway in rat model of DSS-induced colitis. Mol Cell Biochem 374 (2013), 1–11.
26. [26] Kozakova, H., Schwarzer, M., Tuckova, L., Srutkova, D., Czarnowska, E., Rosiak, I., et al. Colonization of germ-free mice with a mixture of three lactobacillus strains enhances the integrity of gut mucosa and ameliorates allergic sensitization. Cell Mol Immunol 13 (2016), 251–262.
27. [27] Spaiser, S.J., Culpepper, T., Nieves, C. Jr., Ukhanova, M., Mai, V., Percival, S.S., et al. Lactobacillus gasseri KS-13, Bifidobacterium bifidum G9-1, and Bifidobacterium longum MM-2 ingestion induces a less inflammatory cytokine profile and a potentially beneficial shift in gut microbiota in older adults: a randomized, double-blind, placebo-controlled, crossover study. J Am Coll Nutr 34 (2015), 459–469.
28. [28] Ling, Z., Liu, X., Cheng, Y., Luo, Y., Yuan, L., Li, L., et al. Clostridium butyricum combined with Bifidobacterium infantis probiotic mixture restores fecal microbiota and attenuates systemic inflammation in mice with antibiotic-associated diarrhea. Biomed Res Int, 2015, 2015, 582048.
29. [29] Wang, H., Gong, J., Wang, W., Long, Y., Fu, X., Fu, Y., et al. Are there any different effects of Bifidobacterium, Lactobacillus and Streptococcus on intestinal sensation, barrier function and intestinal immunity in PI-IBS mouse model?. PLoS One, 9, 2014, e90153.
30. [30] Williams, D.A., Inflammatory cytokines and mucosal injury. J Natl Cancer Inst Monogr 29 (2001), 26–30.
31. [31] Soares, P.M., Mota, J.M., Souza, E.P., Justino, P.F., Franco, A.X., Cunha, F.Q., et al. Inflammatory intestinal damage induced by 5-fluorouracil requires IL-4. Cytokine 61 (2013), 46–49.
32. [32] Sonis, S.T., The pathobiology of mucositis. Nat Rev Cancer 4 (2004), 277–284.
33. [33] Wang, Q., Wang, X.D., Jeppsson, B., Andersson, R., Karlsson, B., Westrom, B., Influence of colostomy on in vivo and in vitro permeability of the rat colon. Dis Colon Rectum 39 (1996), 663–670.
34. [34] Samonte, V.A., Goto, M., Ravindranath, T.M., Fazal, N., Holloway, V.M., Goyal, A., et al. Exacerbation of intestinal permeability in rats after a two-hit injury: Burn and Enterococcus faecalis infection. Crit Care Med 32 (2004), 2267–2273.
35. [35] Eutamene, H., Lamine, F., Chabo, C., Theodorou, V., Rochat, F., Bergonzelli, G.E., et al. Synergy between Lactobacillus paracasei and its bacterial products to counteract stress-induced gut permeability and sensitivity increase in rats. J Nutr 137 (2007), 1901–1907.
36. [36] Yu, Q., Yuan, L., Deng, J., Yang, Q., Lactobacillus protects the integrity of intestinal epithelial barrier damaged by pathogenic bacteria. Front Cell Infect Microbiol, 5, 2015, 26.
37. [37] Ahrne, S., Hagslatt, M.L., Effect of lactobacilli on paracellular permeability in the gut. Nutrients 3 (2011), 104–117.
38. [38] Vijay-Kumar, M., Wu, H., Aitken, J., Kolachala, V.L., Neish, A.S., Sitaraman, S.V., et al. Activation of toll-like receptor 3 protects against DSS-induced acute colitis. Inflamm Bowel Dis 13 (2007), 856–864.
39. [39] Doyle, S.L., O'Neill, L.A., Toll-like receptors: From the discovery of NFkappaB to new insights into transcriptional regulations in innate immunity. Biochem Pharmacol 72 (2006), 1102–1113.
40. [40] Rakoff-Nahoum, S., Paglino, J., Eslami-Varzaneh, F., Edberg, S., Medzhitov, R., Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 118 (2004), 229–241.
41. [41] Kelly, D., Campbell, J.I., King, T.P., Grant, G., Jansson, E.A., Coutts, A.G., et al. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nat Immunol 5 (2004), 104–112.
42. [42] Beg, A.A., ComPPARtmentalizing NF-kappaB in the gut. Nat Immunol 5 (2004), 14–16.
43. [43] O'Hara, A.M., O'Regan, P., Fanning, A., O'Mahony, C., Macsharry, J., Lyons, A., et al. Functional modulation of human intestinal epithelial cell responses by Bifidobacterium infantis and Lactobacillus salivarius. Immunology 118 (2006), 202–215.
44. [44] Chen, J., Rao, J.N., Zou, T., Liu, L., Marasa, B.S., Xiao, L., et al. Polyamines are required for expression of Toll-like receptor 2 modulating intestinal epithelial barrier integrity. Am J Physiol Gastrointest Liver Physiol 293 (2007), G568–G576.
45. [45] Cario, E., Gerken, G., Podolsky, D.K., Toll-like receptor 2 enhances ZO-1-associated intestinal epithelial barrier integrity via protein kinase C. Gastroenterology 127 (2004), 224–238.